Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor + venetoclax + CAG for adult relapsed/refractory T-ALL
ChiCTR2500102412Phase 3Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- May 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of venetoclax, aclarubicin, cytarabine and filgrastim in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Modified composite complete remission rate (mCRc). Planned start May 2025; status: not yet recruiting.
02
Drugs
venetoclaxaclarubicincytarabinefilgrastim
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on ChiCTR2500102412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102412.